Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to -$31.1 million.

  • Tango Therapeutics' Free Cash Flow rose 716.91% to -$31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$146.8 million, marking a year-over-year decrease of 1914.97%. This contributed to the annual value of -$132.3 million for FY2024, which is 1066.62% down from last year.
  • Latest data reveals that Tango Therapeutics reported Free Cash Flow of -$31.1 million as of Q3 2025, which was up 716.91% from -$37.1 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Free Cash Flow registered a high of -$8.0 million during Q2 2021, and its lowest value of -$41.7 million during Q1 2025.
  • Its 5-year average for Free Cash Flow is -$28.4 million, with a median of -$31.1 million in 2025.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 2501865000.0% in 2021, then surged by 2462.44% in 2023.
  • Tango Therapeutics' Free Cash Flow (Quarter) stood at -$17.6 million in 2021, then plummeted by 66.54% to -$29.3 million in 2022, then increased by 5.51% to -$27.7 million in 2023, then tumbled by 32.78% to -$36.8 million in 2024, then rose by 15.41% to -$31.1 million in 2025.
  • Its Free Cash Flow was -$31.1 million in Q3 2025, compared to -$37.1 million in Q2 2025 and -$41.7 million in Q1 2025.